Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9[S]

Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9[S]

Recently, we showed in APOE*3-Leiden cholesteryl ester transfer protein (E3L.CETP) mice that anacetrapib attenuated atherosclerosis development by reducing (V)LDL cholesterol [(V)LDL-C] rather than by raising HDL cholesterol. Here, we investigated the mechanism by which anacetrapib reduces (V)LDL-C...

Full description

Bibliographic Details
Main Authors: Sam J.L. van der Tuin, Susan Kühnast, Jimmy F.P. Berbée, Lars Verschuren, Elsbet J. Pieterman, Louis M. Havekes, José W.A. van der Hoorn, Patrick C.N. Rensen, J. Wouter Jukema, Hans M.G. Princen, Ko Willems van Dijk, Yanan Wang
Format: Article
Language:English
Published: Elsevier 2015-11-01
Series:Journal of Lipid Research
Subjects:
cholesteryl ester transfer protein
cholesterol/metabolism
drug therapy/hypolipidemic drugs
low density lipoprotein/metabolism
lipids
lipoproteins/metabolism
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520354778

Internet

http://www.sciencedirect.com/science/article/pii/S0022227520354778

Similar Items